GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC 50 s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes In Vivo GNF2133 (30 mg/kg; p.o.) shows good oral absorption with oral bioavailability of 22.3% . GNF2133 (30 mg/kg; p.o.; once a day for 5 days) shows the ability to proliferate β-cells in vivo . GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion in RIP-DTA mice . Pharmacokinetic Parameters of GNF2133 in CD-1 mice . plasma (iv) plasma (po) pancreas (po) CL (mL/min/kg) 23.5 / / V ss (L/kg) 11 / / AUC (h·nM) 3268 10974 144420 C max (nM) 1977 1675 13319 t max Form:Solid IC50& Target:DYRK1A 0.0062 μM (IC 50 ) GSK3β >50 μM (IC 50 )
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
GNF2133
CAS number：2561414-56-8 molecular formula：C24H30N6O2
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2561414-56-8 | molecular formula | C24H30N6O2 |
| molecular weight | 434.53 g/mol | Exact mass | ≥98% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
